[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20160348A - Compuestos - Google Patents

Compuestos

Info

Publication number
CR20160348A
CR20160348A CR20160348A CR20160348A CR20160348A CR 20160348 A CR20160348 A CR 20160348A CR 20160348 A CR20160348 A CR 20160348A CR 20160348 A CR20160348 A CR 20160348A CR 20160348 A CR20160348 A CR 20160348A
Authority
CR
Costa Rica
Prior art keywords
disease
activity
compounds
lrrk2 kinases
lrrk2
Prior art date
Application number
CR20160348A
Other languages
English (en)
Inventor
Xiao; Ding
Colin Michael Edge
Yingxia; Sang
Baowei; Zhao
Qian; Liu
Luigi Piero Stasi
Zehong; Wan
Original Assignee
Glaxosmithline Intellectual Property Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithline Intellectual Property Dev Ltd filed Critical Glaxosmithline Intellectual Property Dev Ltd
Publication of CR20160348A publication Critical patent/CR20160348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos novedosos que inhiben la actividad de las cinasas LRRK2, procesos para su preparación, composiciones que las contienen y su uso en el tratamiento o la prevención de enfermedades caracterizadas por la actividad de las cinasas LRRK2, por ejemplo, la enfermedad de Parkinson, la enfermedad de Alzheimer y la esclerosis lateral amiotrófica (ELA).
CR20160348A 2014-01-29 2015-01-28 Compuestos CR20160348A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014000139 2014-01-29
PCT/CN2015/000055 WO2015113452A1 (en) 2014-01-29 2015-01-28 Compounds

Publications (1)

Publication Number Publication Date
CR20160348A true CR20160348A (es) 2017-04-28

Family

ID=53756224

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160348A CR20160348A (es) 2014-01-29 2015-01-28 Compuestos

Country Status (20)

Country Link
US (2) US10087186B2 (es)
EP (1) EP3099695B1 (es)
JP (1) JP6422986B2 (es)
KR (1) KR20160106622A (es)
CN (1) CN105940004B (es)
AU (2) AU2015210593A1 (es)
CA (1) CA2937431A1 (es)
CL (1) CL2016001895A1 (es)
CR (1) CR20160348A (es)
DO (2) DOP2016000195A (es)
EA (1) EA029774B1 (es)
ES (1) ES2802174T3 (es)
IL (1) IL246579B (es)
MA (1) MA39219B1 (es)
MX (1) MX367370B (es)
PE (1) PE20161443A1 (es)
PH (1) PH12016501307A1 (es)
SG (1) SG11201605342UA (es)
UA (1) UA118369C2 (es)
WO (1) WO2015113452A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10339791B2 (en) 2007-06-12 2019-07-02 Icontrol Networks, Inc. Security network integrated with premise security system
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
EA029774B1 (ru) 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
CN105153131B (zh) * 2015-09-21 2017-10-17 马彦丽 一种在护理上治疗人神经胶质瘤的药物组合物
CN105348270B (zh) * 2015-11-09 2018-01-09 吕显艳 一种防治牙体牙髓感染的药物组合物
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
EP3389663A4 (en) 2015-12-16 2019-07-03 Southern Research Institute PYRROLOPYRIMIDINE COMPOUNDS, USE AS LACKERS OF THE LRRK2 KINASE AND METHOD FOR THE PRODUCTION THEREOF
CN105418616B (zh) * 2015-12-26 2018-01-12 山东大学 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
BR112019015278A2 (pt) * 2017-01-25 2020-04-14 Glaxosmithkline Ip Dev Ltd compostos
WO2018155916A2 (ko) * 2017-02-22 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
PT3604304T (pt) * 2017-03-23 2022-11-30 Korea Res Inst Bioscience & Biotechnology Composto derivado de pirrolo-piridina, método para a sua preparação e composição farmacêutica que o contém como substância ativa para prevenção ou tratamento de doenças relacionadas com proteína quinase
KR20200085779A (ko) 2017-12-05 2020-07-15 주식회사 오스코텍 Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
WO2020036437A1 (ko) * 2018-08-16 2020-02-20 재단법인 대구경북첨단의료산업진흥재단 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
AU2019350717A1 (en) * 2018-09-25 2021-05-27 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
CZ308800B6 (cs) * 2019-02-12 2021-05-26 Univerzita Palackého v Olomouci Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci
AU2021371697B2 (en) * 2020-10-29 2024-10-24 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
WO2024056775A1 (en) 2022-09-15 2024-03-21 H. Lundbeck A/S Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504243A (ja) 2003-09-03 2007-03-01 ニューロジェン・コーポレーション ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8029986B2 (en) 2004-10-21 2011-10-04 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
BRPI0617241A2 (pt) 2005-10-13 2016-11-08 Glaxo Group Ltd composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143404A1 (en) 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
KR20120081609A (ko) * 2009-09-29 2012-07-19 글락소 그룹 리미티드 신규 화합물
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
RS56583B1 (sr) * 2010-11-10 2018-02-28 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2014503528A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
CA2831634C (en) 2011-04-21 2019-11-12 Origenis Gmbh Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors
CN103814030A (zh) 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
BR112014012822A8 (pt) * 2011-11-30 2017-07-11 Hoffmann La Roche Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
GB201204985D0 (en) * 2012-03-21 2012-05-02 Genentech Inc Compounds
CN106279202A (zh) 2012-05-03 2017-01-04 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物
JP6218808B2 (ja) 2012-05-03 2017-10-25 ジェネンテック， インコーポレイテッド Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
ES2637245T3 (es) * 2012-06-29 2017-10-11 Pfizer Inc. Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2
EA029774B1 (ru) 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds

Also Published As

Publication number Publication date
PH12016501307B1 (en) 2016-08-15
US10618901B2 (en) 2020-04-14
MX2016009893A (es) 2016-10-31
WO2015113452A1 (en) 2015-08-06
SG11201605342UA (en) 2016-08-30
EP3099695A4 (en) 2017-07-12
MX367370B (es) 2019-08-16
US20180354956A1 (en) 2018-12-13
MA39219B1 (fr) 2018-11-30
JP6422986B2 (ja) 2018-11-14
CN105940004A (zh) 2016-09-14
CA2937431A1 (en) 2015-08-06
JP2017504631A (ja) 2017-02-09
US10087186B2 (en) 2018-10-02
DOP2016000195A (es) 2016-10-31
CN105940004B (zh) 2018-02-02
ES2802174T3 (es) 2021-01-15
EA029774B1 (ru) 2018-05-31
UA118369C2 (uk) 2019-01-10
AU2018200277A1 (en) 2018-02-01
AU2018200277B2 (en) 2019-09-26
DOP2019000010A (es) 2019-03-15
PE20161443A1 (es) 2017-01-06
EP3099695A1 (en) 2016-12-07
CL2016001895A1 (es) 2016-12-09
AU2015210593A1 (en) 2016-07-07
MA39219A1 (fr) 2017-09-29
EP3099695B1 (en) 2020-04-08
PH12016501307A1 (en) 2016-08-15
EA201691514A1 (ru) 2016-12-30
IL246579B (en) 2019-05-30
KR20160106622A (ko) 2016-09-12
US20170015668A1 (en) 2017-01-19
IL246579A0 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
DOP2016000195A (es) Compuestos
UY37808A (es) Nuevos compuestos que inhiben la actividad quinasa de la lrrk2
BR112018001303A2 (pt) ?compostos?
CO2017011851A2 (es) Compuestos novedosos
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
UY37580A (es) Compuestos novedosos que inhiben la actividad de cinasa lrrk2
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
MX2021003905A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
CO2017004465A2 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP17035415A (es) 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
BR112017008045A2 (pt) compostos como inibidores de nik
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112017025263A2 (pt) método para o tratamento de doença neurológica
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas